A Phase II Study of Gimatecan (ST1481) in Locally Advanced or Metastatic Pancreatic Cancer
Status:
Not yet recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This phase II clinical trial studies the safety and effect of as second-line treatmen in
local advanced or metastatic pancreatic cancer. The Gimatecan will be given every four weeks.